Skip to main content
Fig. 4 | Molecular Cancer

Fig. 4

From: Downregulation of MYPT1 increases tumor resistance in ovarian cancer by targeting the Hippo pathway and increasing the stemness

Fig. 4

Downregulation of MYPT1 increases stemness in ovarian cancer cells. a Percentage of paraclones, meroclones and holoclones generated by ES-2, SKOV3 or OVCAR8 ovarian cells expressing shMYPT1, miR-30b or EV. b Left, representative images of tumorspheres formed by ES-2, SKOV3 and OVCAR8 cells expressing shMYPT1, miR-30b or EV. Scale bars: 100 μm. Right, quantification of the number and size of tumorspheres. c Quantification of the number and size of tumorspheres formed by SKOV3 and OVCAR8 cells expressing shMYPT1 or EV from single cells. d Quantification of the percentage of cells that were CD10+, CD133+ or CD19+ (CSC surface markers) by FACS. e Analysis of the expression by RT-qPCR of the stemness-associated genes OCT4, NANOG and SOX2, the CSC-related genes CD44 and EPCAM, as well as MYPT1 and miR-30b, in total cell extracts and tumorspheres from ES-2, SKOV3 or OVCAR8 ovarian cancer cells expressing shMYPT1, miR-30b or EV. f Analysis of the expression of several Hippo pathway target genes, including BIRC5, CTGF, FGF1 and GLI2, by RT-qPCR in tumorspheres from ES-2, SKOV3 or OVCAR8 ovarian cancer cells expressing shMYPT1, miR-30b or EV. The averages and SDs of three independent experiments are shown. Data were analyzed using Student’s t-test. *, P < 0.05; **, P < 0.01; ***, P < 0.001

Back to article page